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In a recent issue of *Critical Care*, Wong and colleagues \[[@B1]\] demonstrated that the serum concentration of IL-27 in critically ill children was a predictor of infection. Our study aims at determining whether platelet activation contributes to the elevated plasma IL-27 concentration. Here we demonstrate that activation of platelets with thrombin receptor activating peptide (TRAP) significantly increased IL-27 levels in supernatants (Figure [1a](#F1){ref-type="fig"}). Moreover, B cells incubated *in vitro*with supernatants from activated platelets upregulated membrane expression of CD86, which was restored to baseline when B cells were pre-incubated with a gp130 blocking antibody (Figure [1b](#F1){ref-type="fig"}). Our data strongly suggest that platelet activation contributes, along with classical sources \[[@B2]\], to elevated plasma levels of IL-27. Recent advances place platelets as an important link between innate and adaptive immunity \[[@B3]\]. Indeed, platelets modulate their inflammatory response after sensing the presence of an infectious agent \[[@B4]\]. Therefore, platelet activation could contribute to increased plasma concentrations of IL-27 along with cytokines such as soluble CD40L \[[@B5]\], and thus may contribute towards immune dysregulation in patients with sepsis.

![**Activated platelets release abundant and functional IL-27**. **(A)**Platelets from apheresis platelet concentrates (n = 11) were stimulated with TRAP-SFFLRN peptide (50 μg/ml, 30 minutes; Sigma-Aldrich, Saint-Quentin Fallavier, France); negative controls were not stimulated. IL-27 concentration in platelet supernatants was determined using a commercial enzyme-linked immunosorbent assay kit (RnD Systems Europe, Lille, France). Thrombin receptor activating peptide (TRAP) stimulation significantly increased IL-27 release from 18.42 ± 2.28 ng/ml to 47.17 ± 2.99 ng/ml (\*\*\**P*\< 0.0005, *t-*test). **(B)**Then, the influence of IL-27-rich platelet supernatants on the expression of the activation marker CD86 was assessed *in vitro*on five independent highly purified blood B lymphocyte sets by means of flow cytometry, in duplicate for each condition. As a control, each set of B cells was incubated in minimal medium for 48 h with recombinant IL-27 (10 ng/ml; RnD Systems). We found that, in contrast to supernatants of non-activated platelets, supernatants of activated platelets provoke a significant increase in CD86 expression on B cells from 21 to 47% (\**P*\< 0.05, *t*-test). CD86 expression was restored to baseline when B cells were pre-incubated with an antibody blocking the gp130 subunit of the IL-27 receptor (0.5 μg/ml; clone 28126, RnD Systems; ^\#^*P*\< 0.05, *t*-test). Results are presented as mean values ± standard deviations.](cc11925-1){#F1}
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